Psychedelic Drugs Market Size - Global Industry, Share, Analysis, Trends and Forecast 2023 - 2032
CHAPTER 1. Industry Overview of Psychedelic Drugs Market
1.1. Definition and Scope
1.1.1. Definition of Psychedelic Drugs
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Psychedelic Drugs Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Psychedelic Drugs Market By Source
1.2.3. Psychedelic Drugs Market By Therapeutic Drugs
1.2.4. Psychedelic Drugs Market By Indication
1.2.5. Psychedelic Drugs Market By Route of Administration
1.2.6. Psychedelic Drugs Market By Distribution Channel
1.2.7. Psychedelic Drugs Market By Region
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Sources
2.2.2. Primary Sources
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restraint 1
3.2.2. Restraint 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Psychedelic Drugs Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Psychedelic Drugs Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Regulatory Compliance
3.9. Competitive Landscape, 2022
3.9.1. Player Positioning Analysis
3.9.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Psychedelic Drugs Market By Source
4.1. Introduction
4.2. Psychedelic Drugs Revenue By Source
4.2.1. Psychedelic Drugs Revenue (USD Billion) and Forecast, By Source, 2020-2032
4.2.2. Synthetic
4.2.2.1. Synthetic Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
4.2.3. Natural
4.2.3.1. Natural Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 5. Psychedelic Drugs Market By Therapeutic Drugs
5.1. Introduction
5.2. Psychedelic Drugs Revenue By Therapeutic Drugs
5.2.1. Psychedelic Drugs Revenue (USD Billion) and Forecast, By Therapeutic Drugs, 2020-2032
5.2.2. Psilocybin
5.2.2.1. Psilocybin Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.3. LSD
5.2.3.1. LSD Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.4. MDMA
5.2.4.1. MDMA Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.5. DMT
5.2.5.1. DMT Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.6. Ketamine
5.2.6.1. Ketamine Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 6. Psychedelic Drugs Market By Indication
6.1. Introduction
6.2. Psychedelic Drugs Revenue By Indication
6.2.1. Psychedelic Drugs Revenue (USD Billion) and Forecast, By Indication, 2020-2032
6.2.2. Alzheimer Dementia
6.2.2.1. Alzheimer Dementia Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.3. Anorexia and Obesity
6.2.3.1. Anorexia and Obesity Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.4. Anxiety
6.2.4.1. Anxiety Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.5. Cluster Headaches
6.2.5.1. Cluster Headaches Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.6. Depressive Disorders
6.2.6.1. Depressive Disorders Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.7. Obsessive Compulsive Disorders
6.2.7.1. Obsessive Compulsive Disorders Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.8. Personality Disorder
6.2.8.1. Personality Disorder Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.9. Post-Traumatic Stress Disorder
6.2.9.1. Post-Traumatic Stress Disorder Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.10. Substance Abuse Disorders
6.2.10.1. Substance Abuse Disorders Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.11. Terminal Cancer Distress
6.2.11.1. Terminal Cancer Distress Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 7. Psychedelic Drugs Market By Route of Administration
7.1. Introduction
7.2. Psychedelic Drugs Revenue By Route of Administration
7.2.1. Psychedelic Drugs Revenue (USD Billion) and Forecast, By Route of Administration, 2020-2032
7.2.2. Oral
7.2.2.1. Oral Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
7.2.3. Injectable
7.2.3.1. Injectable Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
7.2.4. Rectal
7.2.4.1. Rectal Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
7.2.5. Nasal
7.2.5.1. Nasal Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
7.2.6. Transdermal
7.2.6.1. Transdermal Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 8. Psychedelic Drugs Market By Distribution Channel
8.1. Introduction
8.2. Psychedelic Drugs Revenue By Distribution Channel
8.2.1. Psychedelic Drugs Revenue (USD Billion) and Forecast, By Distribution Channel, 2020-2032
8.2.2. Hospital Pharmacies
8.2.2.1. Hospital Pharmacies Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
8.2.3. Retail Pharmacies
8.2.3.1. Retail Pharmacies Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
8.2.4. Online Pharmacies
8.2.4.1. Online Pharmacies Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 9. North America Psychedelic Drugs Market By Country
9.1. North America Psychedelic Drugs Market Overview
9.2. U.S.
9.2.1. U.S. Psychedelic Drugs Revenue (USD Billion) and Forecast By Source, 2020-2032
9.2.2. U.S. Psychedelic Drugs Revenue (USD Billion) and Forecast By Therapeutic Drugs, 2020-2032
9.2.3. U.S. Psychedelic Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
9.2.4. U.S. Psychedelic Drugs Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
9.2.5. U.S. Psychedelic Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
9.3. Canada
9.3.1. Canada Psychedelic Drugs Revenue (USD Billion) and Forecast By Source, 2020-2032
9.3.2. Canada Psychedelic Drugs Revenue (USD Billion) and Forecast By Therapeutic Drugs, 2020-2032
9.3.3. Canada Psychedelic Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
9.3.4. Canada Psychedelic Drugs Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
9.3.5. Canada Psychedelic Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
9.4. North America PEST Analysis
CHAPTER 10. Europe Psychedelic Drugs Market By Country
10.1. Europe Psychedelic Drugs Market Overview
10.2. U.K.
10.2.1. U.K. Psychedelic Drugs Revenue (USD Billion) and Forecast By Source, 2020-2032
10.2.2. U.K. Psychedelic Drugs Revenue (USD Billion) and Forecast By Therapeutic Drugs, 2020-2032
10.2.3. U.K. Psychedelic Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
10.2.4. U.K. Psychedelic Drugs Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
10.2.5. U.K. Psychedelic Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
10.3. Germany
10.3.1. Germany Psychedelic Drugs Revenue (USD Billion) and Forecast By Source, 2020-2032
10.3.2. Germany Psychedelic Drugs Revenue (USD Billion) and Forecast By Therapeutic Drugs, 2020-2032
10.3.3. Germany Psychedelic Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
10.3.4. Germany Psychedelic Drugs Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
10.3.5. Germany Psychedelic Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
10.4. France
10.4.1. France Psychedelic Drugs Revenue (USD Billion) and Forecast By Source, 2020-2032
10.4.2. France Psychedelic Drugs Revenue (USD Billion) and Forecast By Therapeutic Drugs, 2020-2032
10.4.3. France Psychedelic Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
10.4.4. France Psychedelic Drugs Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
10.4.5. France Psychedelic Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
10.5. Spain
10.5.1. Spain Psychedelic Drugs Revenue (USD Billion) and Forecast By Source, 2020-2032
10.5.2. Spain Psychedelic Drugs Revenue (USD Billion) and Forecast By Therapeutic Drugs, 2020-2032
10.5.3. Spain Psychedelic Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
10.5.4. Spain Psychedelic Drugs Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
10.5.5. Spain Psychedelic Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
10.6. Rest of Europe
10.6.1. Rest of Europe Psychedelic Drugs Revenue (USD Billion) and Forecast By Source, 2020-2032
10.6.2. Rest of Europe Psychedelic Drugs Revenue (USD Billion) and Forecast By Therapeutic Drugs, 2020-2032
10.6.3. Rest of Europe Psychedelic Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
10.6.4. Rest of Europe Psychedelic Drugs Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
10.6.5. Rest of Europe Psychedelic Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
10.7. Europe PEST Analysis
CHAPTER 11. Asia Pacific Psychedelic Drugs Market By Country
11.1. Asia Pacific Psychedelic Drugs Market Overview
11.2. China
11.2.1. China Psychedelic Drugs Revenue (USD Billion) and Forecast By Source, 2020-2032
11.2.2. China Psychedelic Drugs Revenue (USD Billion) and Forecast By Therapeutic Drugs, 2020-2032
11.2.3. China Psychedelic Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
11.2.4. China Psychedelic Drugs Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
11.2.5. China Psychedelic Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
11.3. Japan
11.3.1. Japan Psychedelic Drugs Revenue (USD Billion) and Forecast By Source, 2020-2032
11.3.2. Japan Psychedelic Drugs Revenue (USD Billion) and Forecast By Therapeutic Drugs, 2020-2032
11.3.3. Japan Psychedelic Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
11.3.4. Japan Psychedelic Drugs Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
11.3.5. Japan Psychedelic Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
11.4. India
11.4.1. India Psychedelic Drugs Revenue (USD Billion) and Forecast By Source, 2020-2032
11.4.2. India Psychedelic Drugs Revenue (USD Billion) and Forecast By Therapeutic Drugs, 2020-2032
11.4.3. India Psychedelic Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
11.4.4. India Psychedelic Drugs Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
11.4.5. India Psychedelic Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
11.5. Australia
11.5.1. Australia Psychedelic Drugs Revenue (USD Billion) and Forecast By Source, 2020-2032
11.5.2. Australia Psychedelic Drugs Revenue (USD Billion) and Forecast By Therapeutic Drugs, 2020-2032
11.5.3. Australia Psychedelic Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
11.5.4. Australia Psychedelic Drugs Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
11.5.5. Australia Psychedelic Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
11.6. South Korea
11.6.1. South Korea Psychedelic Drugs Revenue (USD Billion) and Forecast By Source, 2020-2032
11.6.2. South Korea Psychedelic Drugs Revenue (USD Billion) and Forecast By Therapeutic Drugs, 2020-2032
11.6.3. South Korea Psychedelic Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
11.6.4. South Korea Psychedelic Drugs Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
11.6.5. South Korea Psychedelic Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
11.7. Rest of Asia-Pacific
11.7.1. Rest of Asia-Pacific Psychedelic Drugs Revenue (USD Billion) and Forecast By Source, 2020-2032
11.7.2. Rest of Asia-Pacific Psychedelic Drugs Revenue (USD Billion) and Forecast By Therapeutic Drugs, 2020-2032
11.7.3. Rest of Asia-Pacific Psychedelic Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
11.7.4. Rest of Asia-Pacific Psychedelic Drugs Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
11.7.5. Rest of Asia-Pacific Psychedelic Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
11.8. Asia Pacific PEST Analysis
CHAPTER 12. Latin America Psychedelic Drugs Market By Country
12.1. Latin America Psychedelic Drugs Market Overview
12.2. Brazil
12.2.1. Brazil Psychedelic Drugs Revenue (USD Billion) and Forecast By Source, 2020-2032
12.2.2. Brazil Psychedelic Drugs Revenue (USD Billion) and Forecast By Therapeutic Drugs, 2020-2032
12.2.3. Brazil Psychedelic Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
12.2.4. Brazil Psychedelic Drugs Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
12.2.5. Brazil Psychedelic Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
12.3. Mexico
12.3.1. Mexico Psychedelic Drugs Revenue (USD Billion) and Forecast By Source, 2020-2032
12.3.2. Mexico Psychedelic Drugs Revenue (USD Billion) and Forecast By Therapeutic Drugs, 2020-2032
12.3.3. Mexico Psychedelic Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
12.3.4. Mexico Psychedelic Drugs Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
12.3.5. Mexico Psychedelic Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
12.4. Rest of Latin America
12.4.1. Rest of Latin America Psychedelic Drugs Revenue (USD Billion) and Forecast By Source, 2020-2032
12.4.2. Rest of Latin America Psychedelic Drugs Revenue (USD Billion) and Forecast By Therapeutic Drugs, 2020-2032
12.4.3. Rest of Latin America Psychedelic Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
12.4.4. Rest of Latin America Psychedelic Drugs Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
12.4.5. Rest of Latin America Psychedelic Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
12.5. Latin America PEST Analysis
CHAPTER 13. Middle East & Africa Psychedelic Drugs Market By Country
13.1. Middle East & Africa Psychedelic Drugs Market Overview
13.2. GCC
13.2.1. GCC Psychedelic Drugs Revenue (USD Billion) and Forecast By Source, 2020-2032
13.2.2. GCC Psychedelic Drugs Revenue (USD Billion) and Forecast By Therapeutic Drugs, 2020-2032
13.2.3. GCC Psychedelic Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
13.2.4. GCC Psychedelic Drugs Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
13.2.5. GCC Psychedelic Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
13.3. South Africa
13.3.1. South Africa Psychedelic Drugs Revenue (USD Billion) and Forecast By Source, 2020-2032
13.3.2. South Africa Psychedelic Drugs Revenue (USD Billion) and Forecast By Therapeutic Drugs, 2020-2032
13.3.3. South Africa Psychedelic Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
13.3.4. South Africa Psychedelic Drugs Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
13.3.5. South Africa Psychedelic Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
13.4. Rest of Middle East & Africa
13.4.1. Rest of Middle East & Africa Psychedelic Drugs Revenue (USD Billion) and Forecast By Source, 2020-2032
13.4.2. Rest of Middle East & Africa Psychedelic Drugs Revenue (USD Billion) and Forecast By Therapeutic Drugs, 2020-2032
13.4.3. Rest of Middle East & Africa Psychedelic Drugs Revenue (USD Billion) and Forecast By Indication, 2020-2032
13.4.4. Rest of Middle East & Africa Psychedelic Drugs Revenue (USD Billion) and Forecast By Route of Administration, 2020-2032
13.4.5. Rest of Middle East & Africa Psychedelic Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
13.5. Middle East & Africa PEST Analysis
CHAPTER 14. Player Analysis Of Psychedelic Drugs Market
14.1. Psychedelic Drugs Market Company Share Analysis
14.2. Competition Matrix
14.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
14.2.2. New Product Launches and Product Enhancements
14.2.3. Mergers And Acquisition In Global Psychedelic Drugs Market
14.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 15. Company Profile
15.1. COMPASS
15.1.1. Company Snapshot
15.1.2. Business Overview
15.1.3. Financial Overview
15.1.3.1. Revenue (USD Billion), 2022
15.1.3.2. COMPASS 2022 Psychedelic Drugs Business Regional Distribution
15.1.4. Product /Service and Specification
15.1.5. Recent Developments & Business Strategy
15.2. Cybin Corp.
15.3. Entheon Biomedical Corp
15.4. F. Hoffmann-La Roche Ltd
15.5. Hikma Pharmaceuticals PLC
15.6. Jazz Pharmaceuticals, Inc.
15.7. Janssen Global Services, LLC
15.8. Pfizer Inc.
15.9. PharmaTher Holdings Ltd.
15.10. usonainstitute.org.
Frequently Asked Questions
What was the market size of the global psychedelic drugs in 2022?
The market size of psychedelic drugs was USD 2.6 billion in 2022.
What is the CAGR of the global psychedelic drugs market from 2023 to 2032?
The CAGR of psychedelic drugs is 10.9% during the analysis period of 2023 to 2032.
Which are the key players in the psychedelic drugs market?
The key players operating in the global market are including COMPASS, Cybin Corp., Entheon Biomedical Corp, F. Hoffmann-La Roche Ltd, Hikma Pharmaceuticals PLC, Jazz Pharmaceuticals, Inc., Janssen Global Services, LLC, Pfizer Inc., PharmaTher Holdings Ltd., and usonainstitute.org.
Which region dominated the global psychedelic drugs market share?
North America held the dominating position in psychedelic drugs industry during the analysis period of 2023 to 2032.
Which region registered fastest CAGR from 2023 to 2032?
Asia-Pacific region exhibited fastest growing CAGR for market of Psychedelic Drugs during the analysis period of 2023 to 2032.
What are the current trends and dynamics in the global Psychedelic Drugs industry?
The current trends and dynamics in the psychedelic drugs industry include growing interest in alternative therapies for mental health disorders, increasing number of clinical trials studying the therapeutic potential of psychedelic drugs, and rising acceptance of psychedelic drugs for medical and therapeutic use.
Which source held the maximum share in 2022?
The natural source held the maximum share of the psychedelic drugs industry.
Select Licence Type
Connect with our sales team
Why Acumen Research and Consulting
100%
Customer Satisfaction
24x7+
Availability - we are always there when you need us
200+
Fortune 50 Companies trust Acumen Research and Consulting
80%
of our reports are exclusive and first in the industry
100%
more data and analysis
1000+
reports published till date
